zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.
Company profile
Ticker
ZYXI
Exchange
Website
CEO
Thomas Sandgaard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
ARIZONA VENTURES INC, CHINA GLOBAL DEVELOPMENT INC, FOX RIVER HOLDINGS INC, IBONZAI COM INC, LIFE MEDICAL TECHNOLOGIES INC /UT/, ZYNEX MEDICAL HOLDINGS INC, ZYNEX MEDICAL HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
Zynex Medical, Inc. • Zynex Monitoring Solutions, Inc. • Zynex NeuroDiagnostics, Inc. • Zynex Europe, ApS • Kestrel Labs, Inc. ...
IRS number
870403828
ZYXI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
12 Mar 24
8-K
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
8-K
Zynex Announces Share Repurchase Program
1 Nov 23
8-K
Zynex Announces Review of Strategic Alternatives
31 Oct 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Zynex Reports Third Quarter 2023 Financial Results
26 Oct 23
8-K
Zynex Announces Share Repurchase Program
11 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Jul 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
8-K
Zynex Reports Second Quarter 2023 Financial Results
27 Jul 23
Transcripts
ZYXI
Earnings call transcript
2023 Q4
29 Feb 24
ZYXI
Earnings call transcript
2023 Q3
26 Oct 23
ZYXI
Earnings call transcript
2023 Q2
27 Jul 23
ZYXI
Earnings call transcript
2023 Q1
27 Apr 23
ZYXI
Earnings call transcript
2022 Q4
13 Mar 23
ZYXI
Earnings call transcript
2022 Q3
27 Oct 22
ZYXI
Earnings call transcript
2022 Q2
29 Jul 22
ZYXI
Earnings call transcript
2022 Q1
29 Apr 22
ZYXI
Earnings call transcript
2021 Q4
25 Feb 22
ZYXI
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.52 mm | 42.52 mm | 42.52 mm | 42.52 mm | 42.52 mm | 42.52 mm |
Cash burn (monthly) | 5.41 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 30.44 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 12.08 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 2.2 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
36.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 121 |
Opened positions | 15 |
Closed positions | 40 |
Increased positions | 37 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 79.11 bn |
Total shares | 11.62 mm |
Total puts | 584.80 k |
Total calls | 72.20 k |
Total put/call ratio | 8.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 1.48 mm | $11.82 bn |
Sandgaard Thomas | 1.43 mm | $13.70 mm |
Vanguard | 1.20 mm | $9.57 bn |
Millennium Management | 949.31 k | $7.59 bn |
Geode Capital Management | 424.63 k | $3.40 bn |
STT State Street | 407.27 k | $3.26 bn |
Renaissance Technologies | 252.74 k | $2.02 bn |
Jupiter Asset Management | 228.73 k | $1.83 bn |
Two Sigma Investments | 227.58 k | $1.82 bn |
Marshall Wace | 214.49 k | $1.72 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jan 24 | Anna Lucsok | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 5,000 | 0.00 | 75,754 |
5 Dec 23 | Daniel J Moorhead | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 5,000 | 0.00 | 90,467 |
27 Oct 23 | Daniel J Moorhead | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 9,178 | 0.00 | 94,262 |
27 Oct 23 | Sandgaard Thomas | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 9,178 | 0.00 | 24,271 |
27 Oct 23 | Anna Lucsok | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 3,671 | 0.00 | 89,623 |
27 Oct 23 | Anna Lucsok | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 5,000 | 0.00 | 85,952 |
News
RBC Capital Maintains Outperform on Zynex, Raises Price Target to $15
1 Mar 24
HC Wainwright & Co. Maintains Buy on Zynex, Raises Price Target to $21
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings Preview: Zynex
28 Feb 24
Zynex Introduces New Products: The Zynex Pro Hybrid LSO And The Zynex DynaComp Cold Compression
20 Feb 24
Press releases
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
22 Feb 24
Zynex Receives FDA Clearance for its Next Generation NMES Device
6 Feb 24
Zynex Recognized in Top 25 Medical Device Companies for 2024
2 Feb 24
Zynex to Participate at the Needham Annual Growth Conference
8 Jan 24